{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:50:32Z","timestamp":1648867832265},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1093\/jac\/dkaa348","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T19:14:39Z","timestamp":1596654879000},"page":"3696-3697","source":"Crossref","is-referenced-by-count":2,"title":["Comment on: Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis"],"prefix":"10.1093","volume":"75","author":[{"given":"Isabel","family":"Spriet","sequence":"first","affiliation":[{"name":"Pharmacy Department, University Hospitals Leuven, Leuven and Department of Pharmaceutical and Pharmacological Sciences, KU Leuven \u2013 University of Leuven, Belgium, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier M","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy E","family":"Peetermans","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Leuven, Belgium and Department of Immunology and Microbiology, KU Leuven \u2013 University of Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, University Hospitals Leuven, Belgium and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, University of Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"2020111305062938300_dkaa348-B1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2020111305062938300_dkaa348-B2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","article-title":"Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial","volume":"51","author":"De Winter","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020111305062938300_dkaa348-B3","year":"2015"},{"key":"2020111305062938300_dkaa348-B4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"Galvez","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2020111305062938300_dkaa348-B5","doi-asserted-by":"crossref","first-page":"e02178","DOI":"10.1128\/AAC.02178-19","article-title":"Population pharmacokinetics of amikacin administered once daily in patients with different renal functions","volume":"64","author":"Arechiga-Alvarado","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111305062938300_dkaa348-B6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13756-019-0535-1","article-title":"Trends in antimicrobial resistance in Israel, 2014-2017","volume":"8","author":"Dickstein","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2020111305062938300_dkaa348-B7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FTD.0000000000000432","article-title":"Therapeutic drug monitoring of gentamicin peak concentrations in critically ill patients","volume":"39","author":"Hodiamont","year":"2017","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3696\/34291405\/dkaa348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3696\/34291405\/dkaa348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T20:07:09Z","timestamp":1616875629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/12\/3696\/5900396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,2]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa348","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,2]]}}}